Calliditas Therapeutics
Renal/hepatic disease therapeutics
Subsidiary of Asahi Kasei Corporation (3407) · Sweden
Assets
(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Budesonide (targeted-release)(TARPEYO / Nefecon) | Approved | Glucocorticoid receptorSmall molecule | IgA Nephropathy |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q2 | $52M | $11M | $75M | $4.4M | report ↗ |
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-Q2 | $26M | $8.4M | $80M | $8.7M | report ↗ |
| 2022-Q2 | $6.5M | $9.8M | $83M | $20M | report ↗ |
| 2022-Q1 | $5.3M | $12M | $88M | $22M | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-FY | $114M | $47M | $97M | $11M | report ↗ |
Calliditas Therapeutics reported revenue of $113.83M, up 43.1% YoY, R&D spend of $47.37M, up 15.3% YoY, cash and equivalents of $96.52M, and a net loss of $43.97M for fiscal year 2023.
Figures only: this period's report disclosed no narrative text